Oral Mucositis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Oral Mucositis – Drugs In Development, 2024 report and make more profitable business decisions.
Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy, and radiation. Symptoms include change in mucosa color, hyposalivation, a change in the integrity of the mucosa, and the presence of edema on the lips and/or the tongue. Treatment includes oral decontamination (mouth care) and oral debridement.
The Oral Mucositis drugs in development market research report provide comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Oral Mucositis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 13 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Oral Mucositis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Oral Mucositis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Oral Mucositis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allander Biotechnologies LLCClevexel Pharma SA
Destiny Pharma Plc
EpicentRx Inc
GlycoMira Therapeutics Inc
iNtRON Biotechnology Inc
Matrix Biomed Inc
MitoImmune Therapeutics Inc
Moberg Pharma AB
Sinopia Biosciences Inc
The Second Affiliated Hospital To Nanchang University
University of Arizona
VasoDynamics Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Oral Mucositis reports